Statement from FDA on continuing efforts to maintain its strong oversight of generic drugs
date:Feb 25, 2019
tions and in evaluating recommendations for enforcement action mean more attention is being given to higher risk facilities than ever before. By better focusing our inspectional resources on higher risk facilities, we can identify potential quality problems that have the most impact on consumers. Then, we can take appropriate action to address our public health concerns.
Overall, our inspections find that most companies are in compliance with good manufacturing practices and other regulations. B
25/35 next page prev page home page last page
go back |  refresh |  WAP home |  Web page version  | login
06/18 19:08